Viewport 04 · Gap Map
The questions consumers ask out loud that no brand is answering
Nine clusters of consumer discourse. Solid lines where the conversation flows. Dotted lines where it does not. The dotted lines are the gaps. Each dotted line is a question consumers ask and no brand has stepped into.
solid = strong bridge · dotted = unowned territory
Three structural gaps · ranked by AXIV's right-to-win
Gap 03 · Natural mucus and decongestion
Where elderberry buyers reach for Mucinex
"I take elderberry every day for immune support. When I'm congested, do I take Mucinex on top of that, or is there a clean alternative I should reach for first?"
What's empty. No brand owns natural mucus management. Sambucol's lozenge gestures at it. Mucinex has no clean frame. The cleanest white-space gap in the consumer-discourse graph.
AXIV right-to-win. Existing SKU breadth (cold/flu plus sinus plus allergy plus DM cough) is already organized by symptom. The architecture matches the gap before any rebrand work.
Gap 02 · The immune-to-acute handoff
Where the daily ritual ends and the heavy stuff begins
"Once I'm already symptomatic, past the first-signs window, does my immune-support product still do anything, or do I have to switch to the heavier OTC stuff?"
What's empty. No brand owns a unified product family from daily immune support through acute treatment through recovery. Sambucol owns the front half. Vicks owns the middle. The handoff is unowned.
AXIV right-to-win. Existing SKU breadth maps to four of the five stages. Adding an immune-support extension would let AXIV story the continuum credibly.
Gap 01 · Trustworthy non-drowsy daytime
Strong enough to clear symptoms, evidence I can trust
"Is there an OTC daytime cold medicine strong enough to clear symptoms but without the phenylephrine, pseudoephedrine, or drowsiness baggage of NyQuil and DayQuil, with evidence I can trust?"
What's empty. Theraflu has adopted phenylephrine-free positioning. No softgel or liquid daytime brand has made it the master claim. The combination of OTC monograph actives, PE-free, non-drowsy, and trusted evidence is unowned.
AXIV right-to-win. Conditional. Requires reformulation off phenylephrine on the Sinus and DayTime SKUs. A product decision before a positioning decision.
Cross-gap territory · adult clean acute care
The shopper who wants clean medicine for adults
Adults who want clean-label OTC at Vicks-and-Tylenol potency, without the family or pediatric register that Genexa and Zarbee's lead with.
What's empty. Genexa owns Clean Medicine but messages family. Zarbee's owns drug-free but messages kids. The adult clean-acute lane is open and defensible: pediatric-first brands cannot easily reposition for adult acute without losing their pediatric-trust register.
AXIV right-to-win. Monograph OTC formulation parity with Vicks and Tylenol. No current pediatric line to dilute an adult-first frame.
What the map shows
The category has dense conversation and a few empty rooms
Nine clusters carry most of the consumer conversation in this vertical. Cold Remedies, Daytime Relief, Immune Boost, Zinc Solutions, Mucus Management, Symptom Coverage, Homeopathic Efficacy, Pediatric Safety, and Overdose Awareness. The first six clusters speak to each other constantly. The last three sit on the edges of the conversation and connect inconsistently. The strongest single bridge in the graph is between Daytime Relief and Cold Remedies. The second-strongest is between Immune Boost and Cold Remedies. Consumers move freely between these rooms because brands have built the doorways.
Three doorways are missing. The first is between Immune Boost and Mucus Management. The shopper who reaches for elderberry daily has no clean answer when she gets congested. She either layers Mucinex on top of her gummy or skips the gummy entirely. The second is between Immune Boost and Daytime Relief. The shopper past the first-signs window has no brand telling her whether her immune support still works or whether she needs to switch to the heavy OTC stuff. The third is between Daytime Relief and Homeopathic Efficacy. The shopper who wants strong daytime relief but does not trust phenylephrine and does not trust homeopathy has no third answer. Theraflu has stepped toward it in hot-drink format. No softgel brand has claimed the territory.
The gaps map onto AXIV's existing SKU shape closely. The Sinus, DM Max cough, Allergy, and DayTime SKUs are already organized by symptom in a way that could plausibly bridge Immune Boost to Mucus Management. The DayTime SKU could plausibly cross Daytime Relief and Homeopathic Efficacy if the phenylephrine question is resolved. The VroZzz line could plausibly bridge the immune-to-recovery arc. The product architecture is closer to the white space than the positioning architecture is. The structural assets exist. They are not currently telling a story.
Methodology appendix
Source graph: axiv-otc-category-2026-05 on InfraNodus. Created 2026-05-18 from a consolidated corpus of six consumer-language research notes via create_knowledge_graph with entity-detection on. Graph statistics: modularity 0.4941 (high topical diversity), 9 clusters, top-nodes-entropy 1.5, top-cluster influence ratio 0.27.
Top betweenness-centrality nodes: zinc (0.263, degree 78), flu (0.252, degree 58), cold (0.235, degree 67), elderberry (0.202, degree 69). Top edges: dayquil-nyquil, zicam-zinc, flu-cold, immune-support, elderberry-syrup, oscillococcinum-homeopathic, oscillococcinum-walmart.
Gap detection via generate_content_gaps; three structural gaps surfaced. Full gap reasoning: research/category-topology/gaps.md. Full deliverable: deliverables/05-structural-gaps.md.